Although HCV-related cirrhotic patients can achieve a sustained virological response (SVR) to IFN-based anti-HCV therapy, the risk of cirrhosis regression and liver cancer may still exist. A long-term…
Known as "xiao qiang" in China, or the "little mighty,” the American cockroach’s recent genome sequencing may help us understand how it earned that nickname.
Hepatitis C (HCV) infects an estimated 150 million people worldwide. It has proven to be a major cause of concern for medical professionals since it can also lead…
Professor Peter Jennings, BPharm, PhD, DSc, at Kings College of London discussed the most promising treatments out there right now for combating Parkinson’s. He discussed the condition to…
According to Lars Brouwers, MD, MSc, a physician and PhD-candidate performing research on 3D-printing in the hospital environment, when doctors use traditional x-ray and 2DCT diagnostic tools in…
Dr. Gregory Goodman is the Founder of the Physician Entrepreneur Summit, an online conference with a mission to inspire the next generation of physician entrepreneurs to solve healthcare’s…
Hepatitis C is an RNA flavivirus that infects 4 million people in the United States, making it the leading indicator for liver transplant in the US. It has…
Scientists take aim at developing a single therapeutic intervention to achieve sustained clotting factor levels adequate enough to prevent bleeding in patient with hemophilia B without needing to…
Deutetrabenazine, a novel VMAT-2 inhibitor, was evaluated in phase 3 trials for the treatment of tardive dyskinesia. The deuterated form of tetrabenazine was found to be well-tolerated, safe,…
